Abstract 52P
Background
Post mastectomy adjuvant radiotherapy (RT) is a critical part in management of breast cancers. Left sided breast cancer cases are at higher risk of developing radiation induced cardiac morbidities. Increased radiation dose to the heart and lung may cause non-breast cancer related mortality and reduce the survival benefits from breast cancer RT. We designed a prospective clinical trial to examine the impact of CPAP on heart and lung during left sided post mastectomy radiotherapy.
Methods
24 left sided post mastectomy patients, after prior consent were included in this study. All patients were simulated in free breathing technique, followed by using CPAP (target pressure 10 to 15 cm of H20). Contouring was done using RTOG guideline. Heart and lung volumes were noted. IMRT virtual plans for both of these techniques were made for all patients using Monaco 5.51.10 software. Mean heart dose, Heart V25, Ipsilateral Lung mean dose, V5, V10, V20 were measured. Mean ± Std values were assessed using Students’ t-test.
Results
Compared to FB, CPAP showed significant difference. Mean heart distance from sternal notch was 6.2 cm and 7.2 cm ;p Value: 0.032 and Mean heart volumes were 354cc and 387cc in the CPAP and FB arms respectively;pValue: 0.665 . Mean left lung volumes were 1281 cc and 1398 cc respectively ;pValue 0.038 favouring CPAP arm. Similarly mean right lung volume of 1552 cc was significantly higher in CPAP arm compared to 1178 cc in FB arm (pValue : 0.041). Heart Dmean was found to be statistically better in CPAP arm (2.5 Gy) compared to FB arm (3.4 Gy) (p Value 0.020). Average V25 of heart was significantly superior in CPAP arm compared to FB arm (0.23% and 2.24% respectively,p Value 0.035). Heart Dmean was 3.1 Gy in CPAP arm compared to 3.7 Gy in FB arm ,pValue: 0.677. Similar result was found for heart V25. CPAP and FB Ipsilateral lung mean dose (6.69Gy and 6.32Gy, pValue: 0.62), Lung V5 (29% and 27.3%, p Value: 0.77), Lung V10 (16.3% and 16.4%, pValue: 0.78), Lung V20 (11.2% and 11.89%, p value 0.22) didn’t show statistical difference.
Conclusions
CPAP is an excellent tool for cardiac sparing in left sided post mastectomy breast cancer cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract